 Privately-held Brii Biosciences, Vir Biotechnology Inc NASDAQ: VIR, and VBI Vaccines Inc NASDAQ: VBIV have dosed the first patient in a Phase 2 trial evaluating BRII-835 VIR-2218 in combination with BRII-179 VBI-2601 for the treatment of chronic HBV infection. The open-label study is designed to evaluate the safety and efficacy of BRII-835 VIR-2218 compared to the combination of BRII-835 VIR-2218 and BRII-179 VBI-2601 with and without interferon-alpha as a co-adjuvant. 